New quinolone antibiotics: A survey of the literature from 2005 to 2010

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 10, 2010, Pages 1295-1319

  Wiles, Jason A ^a   Bradbury, Barton J ^a   Pucci, Michael J ^a  

^a Achillion Pharmaceuticals   (United States)

Author keywords

anti tuberculosis; antibacterial; DNA replication; gyrase; quinolone; quinolone conjugates; quinolone hybrids; topoisomerase; tuberculosis

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; 7 [3 (1 AMINOCYCLOPROPYL) 1 PYRROLIDINYL] 1 (2 FLUOROCYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; ACH 702; AM 1954; ANTOFLOXACIN; BAY 353377; BESIFLOXACIN; BESIVANCE; BOL 303224 A; CIPROFLOXACIN; DC 159A; DELAFLOXACIN; DW 224A; FINAFLOXACIN; GARENOXACIN; GATIFLOXACIN; GF 00100100; ISONIAZID; ISV 403; KRQ 10018; LEVOFLOXACIN; MBX 500; MOXIFLOXACIN; NEMONOXACIN; NORFLOXACIN; OZENOXACIN; PD 0305970; PD 0326448; PGE 960202021; PRULIFLOXACIN; PRUVEL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RX 3341; SITAFLOXACIN; SPARFLOXACIN; SS 734; T 3912; TG 873870; TOSUFLOXACIN TOSILATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WCK 771; WQ 3813; ZABOFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYSTITIS; DIABETIC FOOT INFECTION; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; HELICOBACTER INFECTION; HUMAN; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEPHRITIS; NONHUMAN; PHOTOTOXICITY; PROSTATITIS; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TRAVELLER DIARRHEA; TUBERCULOSIS; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BACTERIAL INFECTIONS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77956697514     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.505922     Document Type: Review

References (125)

1. Hooper DC, Rubinstein E. Quinolone antimicrobial agents. 3rd edition. ASM Press, Washington DC; 2003
2. Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother 2003;51(Suppl S1):13-20
3. Mitscher LA. Bacterial topoisomerase inhibitors: quinolones and pyridone antibacterial agents. Chem Rev 2005;105:559-592
4. Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41(Suppl 2):S144-57
5. Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001;47(Suppl 3):44-48
6. Mugnaini C, Pasquini S, Corelli F. The 4-quinolone-3-carboxylic acid motif as a multi scaffold in medicinal chemistry. Curr Med Chem 2009;16:1746-1767
7. Drlica K, Malik M, Kerns RJ, et al. Quinolone-mediated bacterial death. Antimicrob Agents Chemother 2008;52:385-392
8. Drlica K, Hiasa H, Kerns R, et al. Quinolones: action and resistance updated. Curr Top Med Chem 2009;9:981-998
9. Wang X, Zhao X, Malik M, et al. Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother 2010;65:520-524
10. Bisacchi GS, Dumas J. Recent advances in the inhibition of bacterial type II topoisomerases. Annu Rep Med Chem 2009;44:379-396
11. Bradbury BJ, Pucci MJ. Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 2008;8:574-581
12. Tse-Dinh YC. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious disease. Infect Disord Drug Targets 2007;7:3-9
13. Boteva AA, Krasnykh OP. The methods of synthesis, modification, and biological activity of 4-quinolones (review). Chem Heterocycl Compd 2009;45:757-785
14. Zhang Q, Haemers A. Quinolone antimicrobial agents: structure-activity relationships. Pharmazie 1991;46:687-700
15. Chu DTW, Fernandes PB. Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother 1989;33:131-135
16. Fujimaki K, Noumi T, Saikawa I, et al. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother 1988;32:827-833
17. Fung-Tomc JC, Minassian B, Kolek B, et al. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000;44:3351-3356
18. Marshall SA, Jones RN. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone. Antimicrob Agents Chemother 1993;37:2747-2753
19. Anderson DL. Sitafloxacin hydrate for bacterial infections. Drugs Today 2008;44:489-501
20. Bertino JS, Zhang JZ. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis. Expert Opin Pharmacother 2009;10:2545-2554
21. Xiao Y, Lu Y, Kang Z. Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharm Drug Dispos 2008;29:167-172
22. Harnett SJ, Fraise AP, Andrews JM. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. J Antimicrob Chemother 2004;53:783-792
23. Vasiliou S, Vicente M, Castaner R. Finafloxacin hydrochloride. Drugs Future 2009;34:451-457
24. Higgins PG, Stubbings W, Wisplinghoff H, et al. Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:1613-1615
25. Daiichi. 8-Cyanoquinolonecarboxylic acid derivative. WO2005030752; 2005
26. Fritsche TR, Biedenbach DJ, Jones RN. Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea. Antimicrob Agents Chemother 2009;53:1221-1224
27. Matera MG. Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 2006;19:20-29
28. Park HS, Kim HJ, Seol MJ, et al. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother 2006;50:2261-2264
29. Bhagwhat SS, Mundkur LA, Gupte SV, et al. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob Agents Chemother 2006;50:3568-3579
30. Yamakawa T, Mitsuyama J, Hayashi K. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother 2002;49:455-465
31. Arjona A. Nemonoxacin. Drugs Future 2009;34:196-203
32. Asahina Y, Takei M, Kimura T, et al. Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4] benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-1-substituent. J Med Chem 2008;51:3238-3249
33. Fukuda Y. New approaches to overcoming bacterial resistance. Drugs Future 2009;34:127-136
34. Ma Z, Lienhardt C. Towards an optimized therapy for tuberculosis? Drugs in clinical trials and pre-clinical development. Clin Chest Med 2009;30:755-768
35. Hoshino K, Inoue K, Murakami Y, et al. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother 2008;52:65-76
36. Jones RN, Fritsche TR, Sader HS. Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates. Antimicrob Agents Chemother 2008;52:3763-3775
37. Ryder NS. Discontinued drugs in 2008: anti-infectives. Expert Opin Investig Drugs 2010;19:1-21
38. Bogdanovich T, Esel D, Kelly LM, et al. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Antimicrob Agents Chemother 2005;45:3325-3353
39. Morrow BJ, He W, Amsler KM, et al. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother 2010;54:1955-1964
40. Kazamori D, Suzuki H, Amago T, et al. In vitro activity of WQ-3813 against nosocomial pathogens [abstract F1-1984]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, USA; 2009
41. Suzuki H, Hayashi N, Amago T, et al. WQ-3810, a next generation respiratory fluoroquinolone with outstanding activity against QRSP [abstract F1-2051]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
42. Suzuki H, Hayashi N, Amago T, et al. WQ-3810, a next generation respiratory fluoroquinolone with outstanding activity against QRSP [abstract F1-2051]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
43. Hinman MM, Rosenberg TA, Balli D, et al. Novel antibacterial class: a series of tetracyclic derivatives. J Med Chem 2006;49:4842-4856
44. Buurman ET, Johnson KD, Kelly RK, et al. Different modes of action of naphthyridones in Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 2006;50:385-387
45. Achaogen. Antibacterial fluoroquinolone analogs. WO2009137130; 2009
46. Abu-Sheaib ES, Zahra JA, El-Abadelah MM, et al. Heterocycles [h]-fused onto 4-oxoquinoline-3-carboxylic acid, V [1]. Synthesis and antibacterial activity of some new 2,3-disubstituted 7-oxo-7, 10-dihydropyrido[2,3-f] quinoxaline-8-carboxylic acids an esters. Z Naturforsch 2008;63b:555-563
47. Al-Hiari YM, Qaisi AM, Abu Shuheil MY, et al. Synthesis and antibacterial potency of 4-methyl-2, 7-dioxo-1,2,3,4,7,10-hexahydropyrido, 3-f]quinoxaline-8-carboxylic acid, selected [a]-fused heterocycles and acyclic precursors. Z Naturforsch 2007;62b:1453-1458
48. Murphy ST, Case HL, Ellsworth E, et al. The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents. Bioorg Med Chem Lett 2007;17:2150-2155
49. Warner-Lambert. Quinolone antibacterial agents. WO2005111030; 2005
50. Warner-Lambert. Quinolone antibacterial agents. WO2005026165; 2005
51. Warner-Lambert. Quinolone antibacterial agents. WO2005026145; 2005
52. Warner-Lambert. Azetidinyl quinolones as antibacterial agents. WO2005026146; 2005
53. Houghton TJ, Tanaka KSE, Kang T, et al. Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis. J Med Chem 2008;51:6955-6969
54. Zhu B, Marinelli BA, Goldschmidt R, et al. Synthesis and antibacterial activity of 7-(1,2,3,4-tetrahydropyrrolo[1,2-a]-pyrazin-7-yl) quinolones. Bioorg Med Chem Lett 2009;19:4933-4936
55. AstraZeneca. Heterocyclic urea derivatives for the treatment of bacterial infections. WO2009147433; 2009
56. Asahina Y, Iwase K, Iinuma F, et al. Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin. J Med Chem 2005;48:3194-3202
57. Asahina Y, Araya I, Iwase K, et al. Synthesis and antibacterial activity of the 4-quinolone-3-carboxylic acid derivatives having a trifluoromethyl group as a novel N-1 substituent. J Med Chem 2005;48:3443-3446
58. Efthimiadou EK, Karaliota A, Psomas G. Metal complexes of the third-generation quinolone antimicrobial drug sparfloxacin: structure and biological evaluation. J Inorg Biochem 2010;104:455-466
59. Skyrianou KC, Efthimiadou EK, Psycharis V, et al. Nickel-quinolones interaction. Part 1-Nickel(II) complexes with the antibacterial drug sparfloxacin: structure and biological properties. J Inorg Biochem 2009;103:1617-1625
60. Skyrianou KC, Perdih F, Turel I, et al. Nickel-quinolones interaction. Part 2-interaction of nickel(II) with the antibacterial drug oxolinic acid. J Inorg Biochem 2010;104:161-170
61. Vieira LMM, de Almeida MV, Lourenço MCS, et al. Synthesis and antitubercular activity of palladium and platinum complexes with fluoroquinolones. Eur J Med Chem 2009;44:4107-4111
62. Pucci MJ, Thoma CL, Podos SD, et al. In vitro and in vivo antibacterial activities of ACH-702 [abstract F1-2021]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
63. Thanassi JA, Cheng J, Podos SD, et al. Dual targeting of gyrase and topoisomerase IV by ACH-702 [abstract F1-2022]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
64. Wang Q, Lucien E, Hashimoto A, et al. Isothiazoloquinolones with enhanced antistaphylococcal activities against multi-drug resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions. J Med Chem 2007;50:199-210
65. Kim HY, Pais G, Wiles JA, et al. Optimization of the anti-MRSA activity of 3-aminomethylpyrrolidine-substituted isothiazoloquinolones [abstract F1-2054]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
66. Wiles JA, Hashimoto A, Thanassi JA, et al. Isothiazolpyridones: synthesis, structure, and biological activity of a new class of antibacterial agents. J Med Chem 2006;49:39-42
67. Lenaerts AJ, Bitting C, Woolhiser L, et al. Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob Agents Chemother 2008;52:1513-1515
68. Li Q, Mitscher LA, Shen LL. The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors. Med Res Rev 2000;20:231-293
69. Hutchings KM, Tran TP, Ellsworth EL, et al. Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones. Bioorg Med Chem Lett 2008;18:5087-5090
70. Huband MD, Cohen MA, Zurack M, et al. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob Agents Chemother 2007;51:1191-1201
71. Brotz-Oesterhelt H, Brunner NA. How many modes of action should an antibiotic have? Curr Opin Pharmacol 2008;8:564-573
72. Bremmer JB, Ambrus JI, Samosorn S. Dual action-based approaches to antibacterial agents. Curr Med Chem 2007;14:1459-1477
73. Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res 2008;41:69-77
74. Zhi C, Long ZY, Manikowski A, et al. Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors. J Med Chem 2006;49:1455-1465
75. Butler MM, LaMarr WA, Foster KA, et al. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob Agents Chemother 2007;51:119-127
76. Asahina Y, Nagae O, Sato T, et al. AM-3005: synthesis and in vitro antibacterial activity of novel mutilin-quinolone hybrid antibacterial agent [abstract F1-2030]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
77. Ebisu H, Yamaguchi Y, Ueda R, et al AM-3005, a novel mutilin-quinolone hybrid antibiotic with potent activity against MRSA [abstract F1-2031]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
78. Yamaguchi Y, Ebisu H, Ueda R, et al. AM-3005 (AM), a novel mutilin-quinolone hybrid, possesses potent inhibitory activity against protein synthesis with a type II topoisomerase inhibition [abstract F1-2032]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
79. Robertson GT, Bonventre EJ, Doyle TB, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2313-2323
80. Robertson GT, Bonventre EJ, Doyle TB, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with Staphylococci and Streptococci. Antimicrob Agents Chemother 2008;52:2324-2334
81. GlaxoSmithKline. Novel 6-O-substituted 15-membered 8A-and 9A-lactams. WO2010015703; 2010
82. Glaxo Group Limited/Pliva. Macrolone compounds. WO2006050943; 2006
83. Pliva. Carbamate linked macrolides useful for the treatment of microbial infections. WO2005108413; 2005
84. Pliva. Ester linked macrolides useful for the treatment of microbial infections. WO2005108412; 2005
85. Pokrovskaya V, Belakhov V, Hainrichson M, et al. Design, synthesis, and evaluation of novel-fluoroquinolone-aminoglycoside hybrid antibiotics. J Med Chem 2009;52:2243-2254
86. Pfizer. Antibacterial agents. US7304050; 2007
87. Gordeev MF, Hackbarth C, Barbachyn MR, et al. Novel oxazolidinone- quinolone hybrid antimicrobials. Bioorg Med Chem Lett 2003;13:4213-4216
88. Jazayeri S, Moshafi MH, Firoozpour L, et al. Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. Eur J Med Chem 2009;44:1205-1209
89. Guay DR. An update on the role of nitrofurans in the management of urinary tract infections. Drugs 2001;61:353-364
90. Yu Z, Shi G, Sun Q, et al. Design, synthesis and in vitro antibacterial/ antifungal evaluation of novel 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7(1- piperazinyl) quinoline-3-carboxylic acid derivatives. Eur J Med Chem 2009;44:4726-4733
91. Blom JF, Brutsch T, Barbaras D, et al. Potent algicides based on the cyanobacterial alkaloid nostocarboline. Org Lett 2006;8:737-740
92. Palumed. Hybrid QA molecules wherein Q is an aminoquinoline and A is an antibiotic residue, their synthesis and their uses as antibacterial agent. WO2006024741; 2006
93. Morphochem. Antibacterial active 5-chinolin derivative. WO2007042325; 2007
94. Kamal A, Satanarayama M, Devaiah V, et al. Synthesis and biological evaluation of coumarin linked fluoroquinolones, phthalimides and naphthalimides as potential DNA gyrase inhibitors. Lett Drug Design Discov 2006;3:494-502
95. Zhao X, Quinn B, Kerns R, et al. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 2006;58:1283-1286
96. German N, Wei P, Kaatz GW, et al. Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. Eur J Med Chem 2008;43:2453-2463
97. Merlion. Hybrid antimicrobial compounds and their use. WO2010025906; 2010
98. Hennard C, Truong QC, Desnottes JF, et al. Synthesis and activities of pyoverdin-quinolone adducts: a perspective approach to a specific therapy against Pseudomonas aeruginosa. J Med Chem 2001;44:2139-2151
99. Diarra MS, Lavoie MC, Jacques M, et al. Species selectivity of new siderophore-drug conjugates that use specific iron uptake for entry into bacteria. Antimicrob Agents Chemother 1996;40:2610-2617
100. Md-Saleh SR, Chilvers EC, Kerr KG, et al. Synthesis of citrate-ciprofloxacin conjugates. Bioorg Med Chem Lett 2009;19:1496-1498
101. Rivault F, Liebert C, Burger A, et al. Synthesis of pyochelin-norfloxacin conjugates. Bioorg Med Chem Lett 2007;17:640-644
102. de Almeida MV, Saraiva MF, de Souza MVN, et al. Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives. Bioorg Med Chem Lett 2007;17:5661-5664
103. Carta A, Palomba M, Paglietta G, et al. [1,2,3]Traiazolo[4,5-h] quinolones. A new class of potent antitubercular agents against multidrug resistant Mycobacterium tuberculosis strains. Bioorg Med Chem Lett 2007;17:4791-4794
104. Senthilkumar P, Dinakaran M, Banerjee D, et al. Synthesis and mycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7- (substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids. Bioorg Med Chem 2008;16:2258-2269
105. Sriram D, Senthilkumar P, Dinakaran M, et al. Antimycobacterial activities of novel 1-(cyclopropyl/ tert-butyl/4-fluorophenyl)-1,4-dihydro-6- nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. J Med Chem 2007;50:6232-6239
106. Stella V, Borchardt R, Hageman M, et al. Prodrugs. Springer, New York; 2007
107. Shindikar AV, Viswanathan CL. Novel fluoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. Bioorg Med Chem Lett 2005;15:1803-1806
108. Renau TE, Sanchez JP, Gage JW, et al. Structure-activity relationships of the quinolone antibacterials against Mycobacteria: effect of structural changes at N-1 and C-7. J Med Chem 1996;39:729-735
109. Sriram D, Yogeeswari P, Reddy SP. Synthesis of pyrazinamide Mannich bases and its antitubercular properties. Bioorg Med Chem Lett 2006;16:2113-2116
110. Imramovsky A, Polanc S, Vinsova J, et al. A new modification of anti-tubercular active molecules. Bioorg Med Chem 2007;15:2551-2559
111. Sriram D, Yogeeswari P, Madhu K. Synthesis and in vitro antimycobacterial activity of isonicotinoyl hydrazones. Bioorg Med Chem Lett 2005;15:4502-4505
112. Sriram D, Aubry A, Yogeeswari P, et al. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. Bioorg Med Chem Lett 2006;16:2982-2985
113. Sriram D, Yogeeswari P, Devakaram RV. Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydroazones and amide. Bioorg Med Chem 2006;14:3113-3118
114. Zhao G, Miller MJ, Franzblua S, et al. Synthesis and studies of quinolone-cephalosporins as potential anti-tuberculosis agents. Bioorg Med Chem Lett 2006;16:5534-5537
115. Zhao YL, Chen YL, Sheu JY, et al. Synthesis and antimycobacterial evaluation of certain quinolone derivatives. Bioorg Med Chem 2005;13:3921-3926
116. van den Boogaard J, Kibiki GS, Kisanga ER. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009;53:849-862
117. Gutierrez-Lugo MT, Bewley CA. Natural products, small molecules, and genetics in tuberculosis drug development. J Med Chem 2008;51:2606-2612
118. Sriram D, Banerjee D, Yogeeswari P. Efavirenz mannich bases: Synthesis, anti-HIV and antitubercular activities. J Enzyme Inhib Med Chem 2009;24:1-5
119. Sriram D, Yogeeswari P, Gopal G. Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs. Eur J Med Chem 2005;40:1373-1376
120. Sriram D, Yogeeswari P, Senchani G, et al. Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. Bioorg Med Chem Lett 2007;17:2372-2375
121. Laponogov I, Sohi MK, Veselkov DA, et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol 2009;16:667-669
122. German N, Malik M, Rosen JD, et al. Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2, 4-diones. Antimicrob Agents Chemother 2008;52:3915-3921
123. Malik M, Hoatam G, Chayda K, et al. Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure. Antimicrob Agents Chemother 2010;54:149-156
124. Frothingham R. Glucose homeostatis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005;41:1269-1276
125. Aspinall SL, Good CB, Jiang R, et al. Severe Dysglycemica with the fluoroquinolones: a class effect? Clin Infect Dis 2009;49:402-408